Literature DB >> 16955687

Drug evaluation: Albuferon-alpha--an antiviral interferon-alpha/albumin fusion protein.

Annie T Chemmanur1, George Y Wu.   

Abstract

Human Genome Sciences Inc (HGS), in collaboration with Novartis AG, is developing Albuferon-alpha, a long-acting injectable human interferon alpha2b fusion protein, for the potential treatment of hepatitis C virus (HCV) infection. By May 2004, phase II clinical trials of Albuferon in HCV infection were underway. In June 2006, HGS planned to initiate phase III clinical trials in this indication by the end of 2006. Albuferon also has the potential to treat a broad range of cancers.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16955687

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  4 in total

1.  Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody.

Authors:  Simona Cignetto; Chiara Modica; Cristina Chiriaco; Lara Fontani; Paola Milla; Paolo Michieli; Paolo M Comoglio; Elisa Vigna
Journal:  Mol Oncol       Date:  2016-03-28       Impact factor: 6.603

2.  Enhanced recombinant factor VII expression in Chinese hamster ovary cells by optimizing signal peptides and fed-batch medium.

Authors:  Lin Peng; Xiao Yu; Chengyuan Li; Yanfei Cai; Yun Chen; Yang He; Jianfeng Yang; Jian Jin; Huazhong Li
Journal:  Bioengineered       Date:  2016-04-26       Impact factor: 3.269

3.  A simple, rapid method for evaluation of transfection efficiency based on fluorescent dye.

Authors:  Lin Peng; Wendian Xiong; Yanfei Cai; Yun Chen; Yang He; Jianfeng Yang; Jian Jin; Huazhong Li
Journal:  Bioengineered       Date:  2016-09-27       Impact factor: 3.269

Review 4.  Controversies in and challenges to our understanding of hepatitis C.

Authors:  Robert G Batey
Journal:  World J Gastroenterol       Date:  2007-08-21       Impact factor: 5.742
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.